The Editors of the Journal Ofclinical Investigation Gratefully
Total Page：16
File Type：pdf, Size：1020Kb
Load more
Recommended publications
-
Prospects and Challenges for the Global Nuclear Future: After Fukushima Scott D
Spring_2012_COVER 4/23/2012 10:32 AM Page 3 american academy of arts & sciences spring 2012 www.amacad.org Bulletin vol. lxv, no. 3 Prospects and Challenges for the Global Nuclear Future: After Fukushima Scott D. Sagan, Harald Müller, Noramly bin Muslim, Olli Heinonen, and Jayantha Dhanapala The Future of the American Military Karl W. Eikenberry, John L. Hennessy, James J. Sheehan, David M. Kennedy, and William J. Perry ALSO: Patrick C. Walsh, M.D., Awarded the Francis Amory Prize Humanities Indicators Track Signi½cant Changes in the Disciplines Strengthening Energy Policy through Social Science WikiLeaks and the First Amendment Upcoming Events Special Thanks to Donors APRIL ore than $5.2 million was raised in the ½scal year completed on March 31, 25th M 2012. The Academy’s Annual Fund sur- Project Brie½ng–Washington, D.C. passed the $1.6 million mark for the ½rst The Alternative Energy Future time. Additional gifts and grants totaled Speakers: Steven Koonin (Institute for over $3.6 million, with more than 1,200 in- Defense Analyses; formerly, U.S. Depart- dividuals, 14 foundations, and 54 University ment of Energy); Robert Fri (Resources Af½liates contributing to make these results for the Future); Michael Graetz (Colum- possible. “This was a very successful year,” bia Law School); Michael Greenstone said Alan Dachs, Development and Public (Massachusetts Institute of Technology; Relations Committee Chair. “The Academy Brookings Institution); Kassia Yanosek is fortunate that so many Fellows support (Stanford University; Tana Energy the work we are doing.” Dachs expressed his Capital llc) deep appreciation to the members of the De- velopment Committee during the past year, MAY including Louise Bryson, Richard Cavanagh, 14th Jesse Choper, David Frohnmayer, Michael Reception–New York City Gellert, Matthew Santirocco, Stephen Reception in Honor of New York Area Fellows Stamas, Donald Stewart, Samuel Thier, and Nicholas Zervas, along with the continuing 16th involvement of Board Chair Louis Cabot. -
Dr. Florence P. Haseltine, Ph.D., M.D. Activities of the Foundation While Bringing Recognition to a Worthy Woman in Medicine
The Foundation for the History of Women in Medicine The 14th Annual The Foundation for the History of Women in Medicine, established in 1998, was founded on the belief that knowing the historical past is a powerful force in shaping Alma Dea Morani, M.D. the future. Though relatively young, The Foundation for the History of Women in Medicine has made significant accomplishments in promoting the history of Renaissance Woman Award women in medicine. The Alma Dea Morani Award continues to provide an annual centerpiece to the Dr. Florence P. Haseltine, Ph.D., M.D. activities of The Foundation while bringing recognition to a worthy woman in medicine. This year we honor Florence P. Haseltine, Ph.D., M.D., Emerita Director, Center for Population Research at the Eunice Kennedy Shriver National Institute for Public Health (NICHD) of the National Institutes of Health. The Foundation’s Research Fellowships, offered in conjunction with the The Archives for Women in Medicine (AWM) at Countway Library’s Center for the History of Medicine at Harvard Medical School, continue to be competitive. The 2013 recipient, Dr. Ciara Breathnach, lectures in history and has published on Irish socio-economic and health histories in the nineteenth and twentieth centuries. Her research focuses on how the poor experienced, engaged with and negotiated medical services in Ireland and in North America from 1860-1912. Dr. Breathnach’s focused study of record of the migratory waves against trends in medical and social modernity processes, are held at the Archives for Women in Medicine at the Countway Library and will be weighed against other socio-economic evidence to establish how problematic groups such as the Irish poor affected and shaped medical care in Boston. -
Focal Eosinophilic Myositis Presenting with Leg Pain and Tenderness
CASE REPORT Ann Clin Neurophysiol 2020;22(2):125-128 https://doi.org/10.14253/acn.2020.22.2.125 ANNALS OF CLINICAL NEUROPHYSIOLOGY Focal eosinophilic myositis presenting with leg pain and tenderness Jin-Hong Shin1,2, Dae-Seong Kim1,2 1Department of Neurology, Research Institute for Convergence of Biomedical Research, Pusan National University Yangsan Hospital, Yangsan, Korea 2Department of Neurology, Pusan National University School of Medicine, Yangsan, Korea Focal eosinophilic myositis (FEM) is the most limited form of eosinophilic myositis that com- Received: September 11, 2020 monly affects the muscles of the lower leg without systemic manifestations. We report a Revised: September 29, 2020 patient with FEM who was studied by magnetic resonance imaging and muscle biopsy with Accepted: September 29, 2020 a review of the literature. Key words: Myositis; Eosinophils; Magnetic resonance imaging Correspondence to Dae-Seong Kim Eosinophilic myositis (EM) is defined as a group of idiopathic inflammatory myopathies Department of Neurology, Pusan National associated with peripheral and/or intramuscular eosinophilia.1 Focal eosinophilic myositis Univeristy School of Medicine, 20 Geu- mo-ro, Mulgeum-eup, Yangsan 50612, (FEM) is the most limited form of EM and is considered a benign disorder without systemic 2 Korea manifestations. Here, we report a patient with localized leg pain and tenderness who was Tel: +82-55-360-2450 diagnosed as FEM based on laboratory findings, magnetic resonance imaging (MRI), and Fax: +82-55-360-2152 muscle biopsy. E-mail: [email protected] ORCID CASE Jin-Hong Shin https://orcid.org/0000-0002-5174-286X A 26-year-old otherwise healthy man visited our outpatient clinic with leg pain for Dae-Seong Kim 3 months. -
A Acanthosis Nigricans, 139 Acquired Ichthyosis, 53, 126, 127, 159 Acute
Index A Anti-EJ, 213, 214, 216 Acanthosis nigricans, 139 Anti-Ferc, 217 Acquired ichthyosis, 53, 126, 127, 159 Antigliadin antibodies, 336 Acute interstitial pneumonia (AIP), 79, 81 Antihistamines, 324 Adenocarcinoma, 115, 116, 151, 173 Anti-histidyl-tRNA-synthetase antibody Adenosine triphosphate (ATP), 229 (Anti-Jo-1), 6, 14, 140, 166, 183, Adhesion molecules, 225–226 213–216 Adrenal gland carcinoma, 115 Anti-histone antibodies (AHA), 174, 217 Age, 30–32, 157–159 Anti-Jo-1 antibody syndrome, 34, 129 Alanine aminotransferase (ALT, ALAT), 16, Anti-Ki-67 antibody, 247 128, 205, 207, 255 Anti-KJ antibodies, 216–217 Alanyl-tRNA synthetase, 216 Anti-KS, 82 Aldolase, 14, 16, 128, 129, 205, 207, 255, 257 Anti-Ku antibodies, 163, 165, 217 Aledronate, 325 Anti-Mas, 217 Algorithm, 256, 259 Anti-Mi-2 Allergic contact dermatitis, 261 antibody syndrome, 11, 129, 215 Alopecia, 62, 199, 290 antibodies, 6, 15, 129, 142, 212 Aluminum hydroxide, 325, 326 Anti-Myo 22/25 antibodies, 217 Alzheimer’s disease-related proteins, 190 Anti-Myosin scintigraphy, 230 Aminoacyl-tRNA synthetases, 151, 166, 182, Antineoplastic agents, 172 212, 215 Antineoplastic medicines, 169 Aminoquinolone antimalarials, 309–310, 323 Antinuclear antibody (ANA), 1, 141, 152, 171, Amyloid, 188–190 172, 174, 213, 217 Amyopathic DM, 6, 9, 29–30, 32–33, 36, 104, Anti-OJ, 213–214, 216 116, 117, 147–153 Anti-p155, 214–215 Amyotrophic lateral sclerosis, 263 Antiphospholipid syndrome (APS), 127, Antisynthetase syndrome, 11, 33–34, 81 130, 219 Anaphylaxi, 316 Anti-PL-7 antibody, 82, 214 Anasarca, -
Muscle Biopsy Features of Idiopathic Inflammatory Myopathies And
Autoimmun Highlights (2014) 5:77–85 DOI 10.1007/s13317-014-0062-2 REVIEW ARTICLE Muscle biopsy features of idiopathic inflammatory myopathies and differential diagnosis Gaetano Vattemi • Massimiliano Mirabella • Valeria Guglielmi • Matteo Lucchini • Giuliano Tomelleri • Anna Ghirardello • Andrea Doria Received: 1 August 2014 / Accepted: 22 August 2014 / Published online: 10 September 2014 Ó Springer International Publishing Switzerland 2014 Abstract The gold standard to characterize idiopathic Keywords Inflammatory myopathy Á Autoimmune inflammatory myopathies is the morphological, immuno- myositis Á Histopathology Á Differential diagnosis histochemical and immunopathological analysis of muscle biopsy. Mononuclear cell infiltrates and muscle fiber necrosis are commonly shared histopathological features. Introduction Inflammatory cells that surround, invade and destroy healthy muscle fibers expressing MHC class I antigen are Idiopathic inflammatory myopathies (IIM) are a heteroge- the typical pathological finding of polymyositis. Perifas- neous group of acquired muscle diseases, which have dis- cicular atrophy and microangiopathy strongly support a tinct clinical, pathological and histological features [1, 2]. diagnosis of dermatomyositis. Randomly distributed The most common IIM seen in clinical practice can be necrotic muscle fibers without mononuclear cell infiltrates separated into four categories including polymyositis (PM), represent the histopathological hallmark of immune-med- dermatomyositis (DM), immune-mediated necrotizing iated necrotizing myopathy; meanwhile, endomysial myopathy (NM) and sporadic inclusion body myositis inflammation and muscle fiber degeneration are the two (sIBM) [1, 3]. main pathological features in sporadic inclusion body In the diagnostic workup of an inflammatory myopathy, myositis. A correct differential diagnosis requires immu- muscle biopsy is an indispensable and sensitive tool for nopathological analysis of the muscle biopsy and has establishing the diagnosis. -
NEUROLOGY NEUROSURGERY & PSYCHIATRY Editorial
Journal ofNeurology, Neurosurgery, and Psychiatry 1991;54:285-287 285 J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.54.4.285 on 1 April 1991. Downloaded from Joural of NEUROLOGY NEUROSURGERY & PSYCHIATRY Editorial The idiopathic inflammatory myopathies and their treatment The inflammatory myopathies are the largest group of As new knowledge has accumulated over the course of acquired myopathies of adult life and may also occur in the last 10 years, it has become increasingly clear that there infancy and childhood. They have in common the presence are distinct pathological and immunological differences of inflammatory infiltrates within skeletal muscle, usually between polymyositis on the one hand and dermato- in association with muscle fibre destruction. They can be myositis on the other, though in some cases there is clearly subdivided into those which are due to known viral, an overlap between the two conditions. In polymyositis bacterial, protozoal or other microbial agents and those in there is usually scattered necrosis of single muscle fibres which no such agent can be identified and in which which appear hyalinised in the early stages and are immunological mechanisms have been implicated.' The subsequently invaded by mononuclear phagocytic cells. latter group includes polymyositis, dermatomyositis and Regenerating fibres are usually seen singly or in small inclusion body myositis. The evidence for an autoimmune groups distributed focally and randomly throughout the aetiology consists of: 1) an association with other auto- muscle. The inflammatory cell infiltrate is predominantly immune diseases; 2) serological tests which reflect an intrafascicular (endomysial) surrounding muscle fibres altered immune state; and 3) the responsiveness of rather than in the interfascicular septa, though perivascular polymyositis and dermatomyositis, if not of the inclusion infiltrates may also be found; the cellular infiltrate consists body variety, to immunotherapy.2 Polymyositis may rarely mainly of lymphocytes, plasma cells and macrophages. -
Wheaton College Catalog 2003-2005 (Pdf)
2003/2005 CATALOG WHEATON COLLEGE Norton, Massachusetts www.wheatoncollege.edu/Catalog College Calendar Fall Semester 2003–2004 Fall Semester 2004–2005 New Student Orientation Aug. 30–Sept. 2, 2003 New Student Orientation Aug. 28–Aug. 31, 2004 Labor Day September 1 Classes Begin September 1 Upperclasses Return September 1 Labor Day (no classes) September 6 Classes Begin September 3 October Break October 11–12 October Break October 13–14 Mid-Semester October 20 Mid-Semester October 22 Course Selection Nov. 18–13 Course Selection Nov. 10–15 Thanksgiving Recess Nov. 24–28 Thanksgiving Recess Nov. 26–30 Classes End December 13 Classes End December 12 Review Period Dec. 14–15 Review Period Dec. 13–14 Examination Period Dec. 16–20 Examination Period Dec. 15–20 Residence Halls Close Residence Halls Close (9:00 p.m.) December 20 (9:00 p.m.) December 20 Winter Break and Winter Break and Internship Period Dec. 20 – Jan. 25, 2005 Internship Period Dec. 20–Jan. 26, 2004 Spring Semester Spring Semester Residence Halls Open Residence Halls Open (9:00 a.m.) January 25 (9:00 a.m.) January 27, 2004 Classes Begin January 26 Classes Begin January 28 Mid–Semester March 11 Mid–Semester March 12 Spring Break March 14–18 Spring Break March 15–19 Course Selection April 11–15 Course Selection April 12–26 Classes End May 6 Classes End May 7 Review Period May 7–8 Review Period May 8–9 Examination Period May 9–14 Examination Period May 10–15 Commencement May 21 Commencement May 22 First Semester Deadlines, 2004–2005 First Semester Deadlines, 2003–2004 Course registration -
2019 Impact Report
2019 IMPACT REPORT Honouring Excellence. Preserving History. Inspiring Generations. We invite you to be inspired. FROM OUR BOARD CHAIR AND EXECUTIVE DIRECTOR It is an exciting time at the CMHF as we advance our mission thanks to vital and MISSION meaningful partnerships at many levels and the impacts of our programs in our 25th year of service are detailed well on the pages that follow. We are encouraged that our Recognize and celebrate capacity to do more going forward was strengthened this year with significant partner Canadian heroes whose investments: substantial operational support from the Canadian Medical Association work has advanced (CMA) for three years commencing in 2020 and program support from MD Financial health; inspire the Management across all our programs, including the Discovery Days in Health Sciences pursuit of careers in national presenting sponsorship. the health sciences. Change was also a theme for us in 2019 and it came in many forms: • After 16 years, we transitioned to temporary space at 100 Kellogg Lane in London, VISION ON in anticipation of developing our new Exhibit Hall space and offices in the North A Canada that honours Tower in 2020. This exciting, interactive destination will be home to the Children’s our medical heroes – Museum, an indoor adventure park, retail markets, a boutique hotel and an active those of the past, outdoor courtyard to name a few; an amazing co-location model that means more present and future. guests will experience the sense of pride we know comes with exploring our physical Laureate displays. • We undertook a review of our corporate identity and unveiled a new and contemporary brand, look and feel across all our programs. -
Encyclopedia of Women in Medicine.Pdf
Women in Medicine Women in Medicine An Encyclopedia Laura Lynn Windsor Santa Barbara, California Denver, Colorado Oxford, England Copyright © 2002 by Laura Lynn Windsor All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, except for the inclusion of brief quotations in a review, without prior permission in writing from the publishers. Library of Congress Cataloging-in-Publication Data Windsor, Laura Women in medicine: An encyclopedia / Laura Windsor p. ; cm. Includes bibliographical references and index. ISBN 1–57607-392-0 (hardcover : alk. paper) 1. Women in medicine—Encyclopedias. [DNLM: 1. Physicians, Women—Biography. 2. Physicians, Women—Encyclopedias—English. 3. Health Personnel—Biography. 4. Health Personnel—Encyclopedias—English. 5. Medicine—Biography. 6. Medicine—Encyclopedias—English. 7. Women—Biography. 8. Women—Encyclopedias—English. WZ 13 W766e 2002] I. Title. R692 .W545 2002 610' .82 ' 0922—dc21 2002014339 07 06 05 04 03 02 10 9 8 7 6 5 4 3 2 1 ABC-CLIO, Inc. 130 Cremona Drive, P.O. Box 1911 Santa Barbara, California 93116-1911 This book is printed on acid-free paper I. Manufactured in the United States of America For Mom Contents Foreword, Nancy W. Dickey, M.D., xi Preface and Acknowledgments, xiii Introduction, xvii Women in Medicine Abbott, Maude Elizabeth Seymour, 1 Blanchfield, Florence Aby, 34 Abouchdid, Edma, 3 Bocchi, Dorothea, 35 Acosta Sison, Honoria, 3 Boivin, Marie -
Connective Tissue 5.2.04
Other Connective Tissue Diseases Chester V. Oddis, MD Thomas A. Medsger, Jr, MD Arthur Weinstein, MD Contents 1. Undifferentiated Connective Tissue Disease 2. Idiopathic Inflammatory Myopathy 3. Scleroderma 4. Sjögren’s Syndrome 5. References OTHER CONNECTIVE TISSUE DISEASES 1 1. Undifferentiated Connective Tissue Disease Table 1 The American College of Rheumatology (ACR) has published criteria for several different diseases Clinical Features and Autoantibody Findings commonly referred to as connective tissue disease Possibly Specific for a Defined CTD (CTD). The primary aim of such classification crite - ria is to ensure the comparability among CTD stud - ies in the scientific community. These diseases Clinical Feature include rheumatoid arthritis (RA), systemic sclero - sis (SSc), systemic lupus erythematosus (SLE), Malar rash polymyositis (PM), dermatomyositis (DM), and Sjögren’s syndrome (SS). These are systemic Subacute cutaneous lupus rheumatic diseases which reflects their inflamma - tory nature and protean clinical manifestations with Sclerodermatous skin changes resultant tissue injury. Although there are unifying immunologic features that pathogenetically tie Heliotrope rash these separate CTDs to each other, the individual disorders often remain clinically and even serologi - Gottron’s papules cally distinct. Immunogenetic data and autoanti - body findings in the different CTDs lend further Erosive arthritis support for their distinctive identity and often serves to subset the individual CTD even further, as seen with the myositis syndromes, SLE and SSc. In other cases, it remains difficult to classify individuals Autoantibody with a combination of signs, symptoms, and labora - tory test results. It is this group of patients that have Anti-dsDNA an “undifferentiated” connective tissue disease (UCTD), or perhaps more accurately, an undifferen - Anti-Sm tiated systemic rheumatic disease. -
Pathological Evaluation of Probiotic, Bacillus Subtilis, Against
Journal of American Science, 2011; 7(2) http://www.americanscience.org Pathological Evaluation of Probiotic, Bacillus Subtilis, against Flavobacterium columnare in Tilapia Nilotica (Oreochromis Niloticus) Fish in Sharkia Governorate, Egypt Mohamed H Mohamed and Nahla AG Ahmed Refat Dept of Vet. Pathology, Fac Vet Medicine, Zagazig University, 44519 Zagazig City, Egypt. Nahla_kashmery@hotmail [email protected] Abstract: Fifteen out-of eighty-five of collected Tilapia nilotica fish (17.64%) showing skin lesions, were positive for Flavobacterium columnare with cultural, morphological and biochemical characteristics. These skin lesions were large erosions with loss of scales and red-grayish patches, particularly at the frontal head region and abdomen. All of the positive isolates (Flavobacterium columnare) were molecularly tested by means of PCR. With consistent with F. columnare standard ATCC 49512 strain, these isolates produced a 675 bp band. One hundred apparently healthy Tilapia nilotica fingerlings (30±5 gm) were used to evaluate the effectiveness of probiotic, Bacillus subtilis, in water or diet against the intramuscular challenge with Flavobacterium columnare infection. They were equally divided into 10 groups (10 fish for each group). Five groups were experimental control {placebo (gp 1), intramuscularly infected with 0.2 x108 F. columnare CFU (gp 2), received 0.1 gm/L probiotic in water (gp 3), 0.2 gm /L probiotic in fish diet (gp 4), or 1 gm/L oxytetracycline (gp 5)}; two were prophylactic experiment {received 0.1 (gp 6) or 0.2 (gp 7) gm of probiotic in water and diet, respectively 2 months before bacterial infection and continued for a week later}; and three were treated experiment {intramuscularly infected with 0.2 x108 F. -
By the Numbers Excellence, Innovation, Leadership: Research at the University of Toronto a Powerful Partnership
BY THE NUMBERS EXCELLENCE, INNOVATION, LEADERSHIP: RESEARCH AT THE UNIVERSITY OF TORONTO A POWERFUL PARTNERSHIP The combination of U of T and the 10 partner hospitals affiliated with the university creates one of the world’s largest and most innovative health research forces. More than 1,900 researchers and over 4,000 graduate students and postdoctoral fellows pursue the next vital steps in every area of health research imaginable. UNIVERSITY OF TORONTO Sunnybrook Health St. Michaelʼs Sciences Centre Hospital Womenʼs College Bloorview Kids Hospital Rehab A POWERFUL PARTNERSHIP Baycrest Mount Sinai Hospital The Hospital University Health for Sick Children Network* Centre for Toronto Addiction and Rehabilitation Mental Health Institute *Composed of Toronto General, Toronto Western and Princess Margaret Hospitals 1 UNIVERSITY OF TORONTO FACULTY EXCELLENCE U of T researchers consistently win more prestigious awards than any other Canadian university. See the end of this booklet for a detailed list of awards and honours received by our faculty in the last three years. Faculty Honours (1980-2009) University of Toronto compared to awards held at other Canadian universities International American Academy of Arts & Sciences* Gairdner International Award Guggenheim Fellows National Academies** Royal Society Fellows Sloan Research Fellows American Association for the Advancement of Science* ISI Highly-Cited Researchers*** 0 20 40 60 801 00 Percentage National Steacie Prize Molson Prize Federal Granting Councilsʼ Highest Awards**** Killam Prize Steacie